Abstract

Clorox will release its quarterly results on August 3, 2026 Post Market, and this preview outlines market expectations for revenue, margins, and EPS alongside segment dynamics, near-term operating priorities, and prevailing analyst views ahead of the print.

Market Forecast

Consensus anticipates Clorox to deliver revenue of 1.90 billion US dollars this quarter, a year-over-year decline of 2.07%, with estimated adjusted EPS of 1.64, implying a 25.62% year-over-year decrease; EBIT is forecast at 301.37 million US dollars, down 20.32% year over year. There is no explicit consensus for gross profit margin or net profit margin for this quarter; the market is effectively baking in a moderation from recent levels given the negative EPS and EBIT comparisons. The main business remains concentrated in Health & Wellness, and the market expects a mixed near-term trajectory as price/promo normalization, retailer inventory discipline, and planned brand investments play through. The most promising segment continues to be Health & Wellness, which generated 629.00 million US dollars last quarter and is positioned for above-corporate growth once promotion cadence stabilizes and supply-chain execution benefits from the new operating structure.

Last Quarter Review

Clorox reported revenue of 1.67 billion US dollars (up 0.12% year over year), a gross profit margin of 43.23%, GAAP net profit attributable to the parent company of 187.00 million US dollars, a net profit margin of 11.20%, and adjusted EPS of 1.64 (up 13.10% year over year). Operationally, EBIT reached 296.00 million US dollars, rising 11.28% year over year and exceeding consensus, with adjusted EPS also modestly ahead of expectations. By segment revenue, Health & Wellness contributed 629.00 million US dollars (37.66% of total), Household 482.00 million US dollars (28.86%), Lifestyle 277.00 million US dollars (16.59%), International 285.00 million US dollars (17.07%), and Corporate & Other recorded negative 3.00 million US dollars; segment-level year-over-year growth was not disclosed.

Current Quarter Outlook

Main Business Outlook: Health & Wellness

Health & Wellness, the largest revenue contributor, sits at the center of Clorox’s near-term plans for execution and investment prioritization. Management recently streamlined operating oversight and appointed a chief operating officer to consolidate leadership of all business units with the intent to speed decision-making and sharpen day-to-day execution. The expected benefits for Health & Wellness in this quarter revolve around steadier shelf availability, more targeted promotions, and tighter cost control in manufacturing and logistics that help protect gross margin dollars even as price/mix normalizes. Consensus numbers imply a challenging comparison for earnings this quarter, but the last reported gross margin of 43.23% and net margin of 11.20% provide a helpful baseline. The key watchpoint is promotional elasticity: categories within Health & Wellness tend to react quickly to promotional cadence, and the company’s reset toward more disciplined, ROI-driven trade spend should favor margins even if top-line growth is subdued. Retailer inventory discipline remains a variable, but the rebalanced customer programs and measured shelf pricing should help mitigate volatility and stabilize weekly sell-in flow. From a P&L lens, investors should track the balance between volume recovery and gross-to-net investments. If Health & Wellness can hold share with targeted promotions and capture efficiencies in plant throughput and freight, the segment is positioned to defend contribution margin despite the expected EPS decline at the corporate level. This is particularly relevant because Health & Wellness represented 37.66% of total revenue last quarter; sustaining stability here has an outsized impact on quarterly EPS and cash generation.

Most Promising Segment: Health & Wellness as a Platform for Margin Resilience

Over the next few quarters, Health & Wellness appears best placed to underpin margin resilience and eventual earnings recovery. The company’s internal emphasis on faster-growing categories, coupled with the new COO’s operational background in Cleaning and International, suggests Health & Wellness will continue to benefit from focused resource allocation, streamlined decision rights, and an integrated commercial planning cycle. Last quarter’s 629.00 million US dollars of revenue established a strong base; keeping the segment’s price-pack architecture aligned with household budgets while sustaining brand superiority investments should preserve premium positioning without overreliance on broad-based discounting. In this quarter specifically, the consensus EPS contraction of 25.62% and EBIT decline of 20.32% imply that most of the pressure is coming from margin compression and elevated brand support, rather than an abrupt demand shock. Within Health & Wellness, the tactical objective is to offset promotion and input cost headwinds with procurement savings, manufacturing efficiencies, and improved freight routing. If these execution levers show through in the P&L, any downside risk to the EBITDA bridge should be contained and set up a clearer trajectory into the subsequent quarter. Beyond the near term, Health & Wellness has structural levers that support medium-term returns. These include innovation cadence, value-tier and premium-tier product mix that flexes with consumer budgets, and the ability to scale marketing quickly across core retail partners. The company’s current organizational changes are designed to accelerate these levers by compressing cycle times between planning and execution, and by reinforcing accountability around segment-level targets.

Other Segments and Mixed Near-Term Dynamics

Household delivered 482.00 million US dollars last quarter and remains sensitive to seasonal patterns and shelf price elasticity. The near-term challenge is to calibrate promotion depth to defend core SKUs without eroding unit economics, especially in categories where private label has been active. As the company focuses on value superiority and sharper commercial planning, Household should be able to preserve shelf positions while gradually restoring mix, which is a prerequisite for margin stabilization later in the year. Lifestyle generated 277.00 million US dollars last quarter and typically benefits from innovation and targeted brand-building. In this quarter, trade-down risk and cautious discretionary spending can weigh on premium subcategories, which makes surgical pricing and distribution choices important to sustain sell-through. The company’s centralized leadership model should improve cross-functional coordination between marketing, sales, and supply to keep activation timely and reduce out-of-stocks that disproportionately hurt higher-margin SKUs. International contributed 285.00 million US dollars last quarter and remains a diversified revenue base that can help smooth U.S. category fluctuations. The operational focus in the near term is to manage price-pack architecture and shipping lane reliability, protecting contribution margin while navigating retailer replenishment rhythms. As the new operating structure improves accountability and reduces cycle-time variability, International can add incremental stability to corporate EBIT even if top-line growth remains modest this quarter.

Stock Price Drivers This Quarter

The first determinant will be how the gross-to-net trade-off lands in reported margins. Consensus does not provide a specific gross margin forecast, but the direction from estimates—a 2.07% revenue decline and a 25.62% EPS decline—signals the market expects heavier brand and promotion investment alongside cost headwinds. If reported gross margin proves more resilient than feared, the downside surprise embedded in EPS estimates may unwind quickly. The second determinant is management’s update on the simplified operating structure and leadership changes. Investors will look for tangible proof points that the COO-led model is compressing decision times, improving on-shelf availability, and aligning investment toward higher-return categories. Execution color—such as procurement savings, freight and warehousing efficiency, and SKU-level promotion outcomes—will be crucial to shaping the market’s conviction about second-half run-rate earnings. The third determinant is the tone on guidance and capital allocation. Earlier in the year, the company trimmed its full-year outlook amid rising costs and weak demand pockets, which reset expectations lower. Any signs that costs are tracking better than plan, or that promotional elasticity is favorable without materially diluting mix, would influence both multiple expansion and near-term price action. Conversely, if management signals incremental pressure in larger U.S. categories or heightened brand support needs, the market may extrapolate a slower earnings recovery path into subsequent quarters.

Analyst Opinions

Across recent commentary that conveys a directional stance, bearish views outnumber bullish ones by roughly 75% to 25%. Goldman Sachs maintains a Sell rating, citing the risk that heavier promotional investments and cost pressures cap near-term earnings recovery. Evercore ISI reiterates Underperform, emphasizing a challenging setup for margins and a need for clearer evidence that execution changes will translate into sustainably higher returns. JPMorgan stays Underweight, reflecting concerns that the balance between defending volumes and preserving price/mix could keep EPS under pressure in the near term despite operational progress. On the minority bullish side, Jefferies remains Buy, but the broader rating mix leans neutral-to-cautious as multiple firms have either lowered price targets or retained Hold/Equalweight/Neutral stances into the print. The skew toward bearish/underweight opinions appears anchored in the same data points the market is modeling: a 2.07% year-over-year decline in revenue, a 20.32% decline in EBIT, and a 25.62% decline in adjusted EPS for this quarter. Those estimates imply that even if topline holds relatively steady, the P&L bears the weight of elevated brand support and normalized promo activity, with limited room for input-cost relief to flow through immediately. Importantly, several neutral-to-cautious frameworks highlight corporate actions now underway. The company announced a simplified operating structure, placed all business units under a single COO to improve execution, and began a CEO search process following an announced transition for health reasons. Bearish analysts argue that while these steps are strategically sensible, they introduce near-term uncertainty and will take time to yield measurable financial benefits. The consensus view among the majority bearish camp is that execution proof points must show up in the quarterly numbers—through steadier gross margin, healthier contribution by the Health & Wellness portfolio, and signs that promotional elasticity is improving—before the stock can rerate. Synthesis of the majority perspective points to a practical playbook for the upcoming report: investors want to see that the company can defend last quarter’s 43.23% gross margin baseline while managing a disciplined level of promotion, generate enough operational savings to blunt the EPS compression signaled by estimates, and offer credible, quantifiable milestones under the new operating structure. To shift the debate, the company will likely need to demonstrate that Health & Wellness can grow above the corporate average without sacrificing unit economics and that Household and Lifestyle can stabilize mix as brand investments scale. Until such evidence is visible in reported numbers, the majority of institutional commentary remains cautious into this quarter’s print.